ReviewComputational and mathematical methods in medicine2013
Genomic biomarkers for personalized medicine: development and validation in clinical studies.
Review in Computational and mathematical methods in medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review.Discover oncology · 2022Review
- Progress Toward a Multiomic Understanding of Traumatic Brain Injury: A Review.Biomarker insights · 2022Review
- EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer.BMC medical genomics · 2021Article
- Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.Pharmaceutics · 2020Review
- Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality.Frontiers in psychiatry · 2020Review
- Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design.Contemporary clinical trials communications · 2019Review
- Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Journal of personalized medicine · 2017Review
- Privacy and security in the era of digital health: what should translational researchers know and do about it?American journal of translational research · 2016Article
- Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.PloS one · 2016Review
- Molecular biomarkers for grass pollen immunotherapy.World journal of methodology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The establishment of high-throughput technologies has brought substantial advances to our understanding of the biology of many diseases at the molecular level and increasing expectations on the development of innovative molecularly targeted treatments and molecular biomarkers or diagnostic tests in the context of clinical studies. In this review article, we position the two critical statistical analyses of high-dimensional genomic data, gene screening and prediction, in the framework of development and validation of genomic biomarkers or signatures, through taking into consideration the possible different strategies for developing genomic signatures. A wide variety of biomarker-based clinical trial designs to assess clinical utility of a biomarker or a new treatment with a companion biomarker are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.